checkAd

    EQS-News  310  0 Kommentare Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil) - Seite 3


    End of Media Release

    Language: English
    Company: RELIEF THERAPEUTICS Holdings AG
    Avenue de Sécheron 15
    1202 Genève
    Switzerland
    E-mail: contact@relieftherapeutics.com
    Internet: https://relieftherapeutics.com
    ISIN: CH0100191136
    Listed: SIX Swiss Exchange
    EQS News ID: 1179458

     
    End of News EQS Group News Service

    Lesen Sie auch

    1179458  30.03.2021 

    fncls.ssp?fn=show_t_gif&application_id=1179458&application_name=news&site_id=wallstreet
    Seite 3 von 3




    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-News Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil) - Seite 3 EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil) 30.03.2021 / 07:00 Relief Confirms Release of 60-Day Findings …